Shelley Amster has worked in the life science and health industries for more than 30 years beginning with her research on infertility and women’s health, causes that she remains committed to. She currently serves as founder and principal at ShelleyCO, a life science business development consulting firm, and also serves as a business development and marketing advisor for both CATALENT (previously Juniper Pharma Services) and DxNow, Inc. Shelley serves on the Board of Directors for BioSurplus, Inc., a premier provider of pre-owned lab equipment and liquidation services. Shelley is committed to helping connect emerging life science companies with her vast network of investors, strategic partners, and resources, and is an active mentor and role model for the entrepreneurs and scientists of tomorrow.
CEO of Bulbrook/Drislane Brokerage, a national distributor of financial products headquartered in the Boston area. For more than 30 years John has helped insurance agents, financial planners and brokers find the right insurance and annuity products to meet their clients’ needs. In the process, he has earned a reputation throughout the industry for his integrity, resourcefulness and hard work, all carried out in good humor. Representing more than 40 insurance and annuity companies with his business partner Rick Drislane, John is in the enviable position of being able to help his agents identify the best policy at the best value for situations both simple and complex. John is the Lead Independent Trustee of the Pear Tree Mutual Fund Group, with over two billion dollars of assets.
John is an experienced leader in the pharmaceutical and biotech industry. His careers in the industry spanned 36 years and were all spent with Sanofi and its legacy companies. John played an important role in five significant mergers spanning the time from Marion Laboratories to the acquisition of Genzyme by Sanofi. John’s final leadership role was as Chief Commercial Officer and Sr. VP of Sanofi’s Global Oncology Division. In this role John provided the Commercial leadership to the $3.5 bn Oncology franchise in six regions and 90 countries. During his tenure Jevtana was launched the first product indicated for second line metastatic prostate cancer. Eloxatin intellectual property was defended, Taxotere indications were expanded and the Genzyme Transplant and Oncology organization were integrated into the Sanofi Oncology Team.
Tom is the General Partner of the Keery Family Limited Partnership, a real estate partnership with commercial and residential properties in Massachusetts. Prior to entering the real estate business, Tom was president of Frost Motors Inc., a Newton, MA dealership holding company. In operation since 1934, Tom joined the family business upon his graduation from Ithaca College in 1975 with a degree in Communications. Since 1985, Tom had been the Dealer Principal, and had successfully grown the business, acquiring and selling several dealerships. In 2002, he was named the Massachusetts recipient of Time Magazine's Quality Dealer Award, which is given annually to automobile dealers in recognition of their leadership in community and Industry affairs.
Emotionally intelligent, entrepreneurial Executive in the pharmaceutical and biotechnology industry with multiple drugs approved and approaching approval. These products are projected to be multi-billion dollar products and have created over $6 billion in market capitalization. Built and led successful teams in pharmaceutical research and development with over three decades of experience. Leadership positions include Executive position in business development for a top tier research medical school, decade long tenure as Executive Committee member of a publicly traded company, SVP of Global Research, and SVP of Quality. Directed internal and external international relationships. Therapeutic areas include Rare Diseases, Hemophilia, Pain, Oncology, Antivirals.
Cross-functional team leader in healthcare, biopharma, and technology corporate partnerships. Business and product experience leading strategic alliances and BD. Manage end-to-end deal cycles while working with technical, legal and investor audiences. Management consulting and analyst experience in health outcomes research, financial modeling, and market opportunity assessments. Market research and marketing in Oncology, CNS, Dialysis, and hospital markets; healthcare data analytics; population health and value-based care.